genetics, inflammation, imaging depending on background and expertise Stay up to date on clinical, disease, biology and scientific literature and competitor data for their respective disease areas Implementing strategies in close collaboration with the BMD global organization which includes over 100 associates with expertise in all aspects of biomarker science i.e. genetics, genomics, molecular and cellular, digital devices, imaging and data sciences Essential Requirements: MD, MD/PhD, or PhD degree required, plus additional PhD/postdoc or equivalent level research Deep understanding of cardiovascular and metabolic disease epidemiology that can be applied to questions of diagnosis, biomarker development and treatment monitoring strongly preferred Scientific excellence supported by recognized high quality publications; clinical and/or biological expertise in cardiovascular and metabolic diseases (Board certified or similar level preferred) Experience performing similar role within a pharmaceutical/biotechnology research company, clinical research organization or academic medical center Significant relevant experience after your MD/PhD/postdoc including quantitative expertise in biostatistics, bioinformatics, computer biology, statistical genetics, clinical imaging, machine learning, or data science; interpreting and publishing studies consisting of "omics" data e.g. Key responsibilities: Delivering clinical project and disease biomarker strategies and plans across the early phase Cardiovascular and Metabolism portfolio and support relevant mature assets in the late phase portfolio Leading a dedicated matrixed group of Subject Matter Experts and project team representatives as well as key program stakeholders, to together develop biomarkers strategies for disease and/or assets across the Research-Development-Commercial continuum Representing Biomarker Development on Cardiovascular and Metabolism early and late Disease Area Decision Boards to identify, develop, and drive cardiovascular and metabolic disease and compound mechanistic biology, and precision medicine approaches for the portfolio Leading strategic translational data working groups centered on integrating and analyzing large-scale patient muti-modal data sets (omics, imaging, digital, etc.) to identify new indications, endpoints, and responsive patient subpopulations Providing thought leadership with other BMD TABLs to identify synergies and drive innovation across our large and diverse clinical portfolio.